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Summary.-The effect of successive inocula of tumour cells given to rats at intervals
of 1 to 10 days was examined. If W256 cells were injected on both occasions, the
second inoculum failed to grow if given into the footpad as early as 1 day, or intra-
venously as soon as 4 days, after the first administration. However, although a
second inoculum failed to grow, it produced significant augmentation ofthe growthof
the primary implant if given during its latent or growth phases. If the second
inoculum contained cells from a fibrosarcoma unrelated to W256, its growth was
effectively curtailed if the initial inoculum had preceded it by 24 h or more. However,
secondary inocula of fibrosarcoma cells did not augment the growth of the primary
W256 tumour.
ALTHOUGH tumour-bearing hosts mount
immune responses to both autochthionous
and transplanted tumours, these responses
are inadequate to prevent progressive
growth (Alexander and Hall, 1968;
Brunner et al., 1968; Hellstrom, Hellstrom
and Pierce, 1968; Klein et al., 1960;
Mikulska, Smith and Alexander, 1966).
Whilst spontaneous regression of a well
established primary tumour is infrequent,
the host is often resistant both to second-
ary implants and to the establishment of
metastases from the primary tumour,
provided that growth of this is still in
progress (Bashford et al., 1908; Deckers
et al., 1973; Gershon and Kondo, 1971).
Whilst the influence of a primary tumour
on the establishment and growth of
spontaneous or artificially induced second-
ary tumours has been thoroughly docu-
mented, there have beenfew investigations
of the influence of the second implant on
the growth of the primary. Yet this effect
may be particularly relevant to clinical
observations in humans, where an appar-
ent change in the growth pattern of the
primary tumour could be due to the estab-
lishment of metastases. Indeed reports of
animal studies suggest that secondary
tumours may produce considerable effects
on the growth of the primary (Cheshire,
1970; Dewys, 1972; Yuhas and Pazmifno,
1974).
This paper reports the influence of a
second challenge with cells from the same
or a different tumour on the growth of a
non-lethal tumour which had been inocula-
ted previously. The first tumour can be
inferred to have induced an immunological
response as, after its regression, hosts are
resistant to a second implant. The influ-
ence ofthe second challenge on the growth
of the first implant, and the extent of
immunity of the host towards a second
challenge, were examined following re-
administration of tumour cells at different
sites during either the growth or regression
phases of the first implant.
MATERIALS AND METHODS
Rats. Seven- to 9-week-old male and fe-
male (PVG/c x DA) F1 hybrid rats were used.
* Present address: Central Laboratory, Netherlands Red Cross Bloo(itransfusion Service, Postbus 9190,
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In any individual experiment, rats of the
same sex and age were used.
Tumours.-The Walker 256 carcinoma
(W256) was obtained from Dr M. Cauchi,
Monash University, Melbourne. W256 cells
were cultured in 250ml Falcon plastic tissue-
culture flasks in Medium F15 (Eagle's mini-
mum essential medium, Gibco, U.S.A.)
supplemented with 10% foetal calfserum and
100 u/ml Mycostatin. W256 cells were harves-
ted in Puck's saline containing 0 025% tryp-
sin and 0-01% versene. Tumour cells were
washed twice in Hanks' balanced salt solution
(HBSS) and their viability was established by
the use of0.1% trypan blue in saline. In order
to avoid the preferential selection of certain
cells under tissue culture conditions, new
tumour-cell cultures were set up each month
from a stock vial stored in liquid N2-
The fibrosarcoma used arose spontaneously
in a (Lewis xDA) F1 hybrid male rat and was
adapted to the same tissue-culture conditions
as the Walker 256 carcinoma.
Tumour inoculation.-Recipients were an-
aesthetized with ether. Footpad injections
(0.1-0-2 ml) were given into the subcutaneous
tissue in the middle of the foot, the needle
being inserted just distal to the heel. The
lateral tail vein was used for i.v. injections
(1-3 ml).
Tumour growth measurement.-Footpad size
was measured on alternate days after tumour-
cell inoculation. Anaesthetized rats were
examined inrandom orderusing calipers (Dial
Caliper, Mitutoyo, Japan) with an accuracy
of 0 1 mm. On the first day after the injection
of tumour cells in HBSS or HBSS alone, a
small footpad swelling was observed. The
swelling had, however, completely regressed
by the 4th day in the saline-injected controls,
the time at which the first experimental
readings were taken. At the doses used here
fori.v. injection, assessment oftumourgrowth
was an all-or-none pnenomenon, based on the
death of the host due to complete replace-
ment oflung tissue bytumour, or his survival.
RESULTS
The injection of W256 cells into the s.c.
tissues of the footpad initated localized
tumour growth. The consequences of
injecting a variety ofdoses ofviable W256
cells into the footpad of normal (PVG/c x
DA) F1 hybrid rats are shown in Fig. 1. A
dose ofat least 5 x 107 cells was required to
ensure a lethal outcome to tumour growth,
following non-reversible metastatic spread
to the popliteal lymph node, the leg
muscles and finally the lungs. Following
injection of non-lethal doses, the tumour
growth pattern took the form of a latent
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FIG. 1. Changes in footpad thickness follow-
ing the s.c. injection of various numbers of
W256 cells.
Normal (PVG/c x DA) F1 hybrid rats were
injected in one hind footpad with the indi-
cated number of viable W256 cells. Each
group consisted of 5 recipients. 0* 0
105 cells; A A 106 cells; 0- O 107
cells; * * 5 x 107 cells. Following
this injection of tumour cells all recipients
died. Mean survival time was 18-6 + 3-3
days.
period varying in length from 4 to 7 days
followed by a growth phase of about 7-10
days, when tumour cells could be seen in
the draining lymph node, and then by a
regression phase with concurrent dis-
appearance oftumour cellsfrom the lymph
node. Inoculation of 5 x 105 cells resulted
in tumour growth in the footpads of 100%
ofnormalF1 hybridrats. Astumourgrowth
rate varied with the batch of W256 cells,
each experiment included a control group
of rats which were inoculated in the foot-
pad with W256 cells, but received no other
treatment. Tumour growth in the footpads
of the rats in the experimental groups was
assessed in comparison with tumour
growth in these control rats. For this
reason no mean values could be calculated
using data from experiments done on
different days, and in the following para-
graphs the results ofone characteristic test
are given for each experimental protocol.
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The effects of a second challenge with the
same tumour
(PVG/c x DA) F1 hybrid rats were
injected in the left footpad with 5 x105
viable W256 cells. At various times after
this injection, a similar number of W256
cells was administered into the contra-
lateral footpad. The times chosen for the
second injection, namely 1, 7, 14 and 30
days, fell within the latent, growth,
regression and post-regression phases of
the first implant respectively. The results
of one characteristic experiment are sum-
marized in Fig. 2. In no case did the second
inoculum of W256 cells give rise to tu-
mours in the footpads of previously chal-
lenged rats. However, thesecondinoculum,
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FIG. 2.-The effect ofre-challenge with W2'
cells on the growth in the contralater
footpad of an earlier inoculum. Fin
groups, each of 5 normal (PVG/c
DA) F1 hybrid rats, were injected wil
5 x 105 viable W256 cells in the le
footpad. One group received no other trea
ment while the 4 remaining groups we:
challenged in the right footpad with
similar number of W256 cells at variol
intervals after the primary injection. I
those groups re-challenged 14 and 30 da:
after the first injection, growth of the fir,
tumour did not differ significantly froi
that observed in the control group. TI
results of the groups injected at 14 and i
30 days have therefore been omittei
A A Control group. No second inje4
tion of W256 cells. * * Re-challeng with W256 cells 1 day after initial injectioi
Growth of first tumour was significant]
augumented (P = 0-01) over the contr
group at both 10 and 12 days. O(
Re-challenge with W256 cells 7 days aft
initial injection. Growth of first tumou
was significantly augmented (P = 0-04) E
10 days.
if given during the latent or growth
phases of the first implant, effected a
significant augmentation of the growth of
the first implant in comparison with
tumour growth in the footpads of rats in
the control group. If the second challenge
was deferred until the regression phase of
the first implant, this tumour continued to
decrease in size as in control rats, until the
footpad regained its normal thickness.
The preceding experiment did not
indicate whether the antigenic stimulus
provided by the second challenge was
sufficient of itself to produce the observed
effects, or whether activity was required
on the part of the tumour cells in the
second inoculum. To clarify this point, the
experiments were repeated with the substi-
tution of lethally irradiated (10,000 rad)
W256 cells in the re-challenge inoculum. A
dose of 5x 105 W256 cells was used again,
and the tumour-bearing hosts were chal-
lenged with irradiated cells either 1, 2, 5,
6, or 7 days after the first inoculation. In
contrast to the experience with a second
inoculum of viable cells, no change was
observed in the growth ofthe first implant
at any time.
It was inferred from the preceding
25 experiments that, whereas re-challenge
with tumour antigen alone was insufficient
56 to modify the growth of the tumour im- al planted first, the injection of a non-lethal
vXe dose of viable tumour cells into the x
th contralateral footpad, ifadministered suit-
ft ably early after the first challenge, aug-
Lte mented the growth of the first tumour. It ire
a was of interest to determine whether
us
growth would be augmented in the
ys primary implant ifthe second inoculum of
-st tumour cells were to grow progressively to
he a lethal conclusion. 5 x 106 W256 cells are
at uniformly lethal if injected i.v. This dose
d- of W256 cells was administered to rats on
iCe Days 1 to 5 after the injection of 5x 105
n. W256 cells into thefootpad, andthe effects
[y of this manoeuvre on both the growth of
o the first tumour in the footpad and the
er survival ofthe host aresummarizedinFig.
irt 3. During the first 3 days after footpad
challenge with W256 cells, no more than a
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IG. 3.-The effect of a second i.v. inoculum
of W256 cells on the growth of a primary
inoculum in the footpad. Six groups, each of
5 (PVG/c x DA) F1 hybrid rats, were in-
jected in the footpad with 5 x 105 viable
W256 cells. At various intervals after the
initial injection, inocula of 5 x 106 W256
cells were given i.v. As insufficient W256
cells were available from tissue culture to
inject all groups ofratswith the same batch,
two batches, A and B, each with its own
control group, were used. (A) A*-
Control group. No. W256 cells injected i.v.
* * W256 cells injected i.v. 1 day
after footpad inoculation. All recipients
died. Mean survival time 19-6 i 1-3 days.
O O W256 cells injected i.v. 3 days
after footpad inoculation. One rat sur-
vived indefinitely whilst the other 4 died
after a mean survival time of 48-5 ± 2-1
days. The mean survival time of rats not
injected in the footpad with W256 cells
before an i.v. injection was 16*4± 0 4 days.
(B) A Control group. *
W256 cells injected i.v. 4 days after footpad
inoculation. All recipients survived and
there was no significant augmentation of
the growth of the footpad tumour.
marginal protective effect against i.v.
injected tumour cells could be demonstra-
ted. Tumour-bearing hosts which had
been re-challenged i.v. on the 2nd and 3rd
days after challenge in the footpad surviv-
ed significantly longer than normal rats
injected i.v. with tumour cells alone,
although only one out of 10 rats survived
indefinitely. Tumour growth in the foot-
pads of rats which had been re-challenged
i.v. during the 3 days after the initial
footpad inoculation was significantly aug-
mented and progressed until death. How-
ever, i.v. injections of 5 x 106 W256 cells
given on the 4th or later days after injec-
tion oftumour cells into the footpad failed
to influence the growth of the initial
tumour, and did not kill the recipient.
The effects of a second challenge with a
different tumour
To determine the specificity of the
effects observed in the preceding experi-
ments, the effect ofsubstituting cells from
an unrelated tumour in the second inocu-
lum was examined. The additional tumour
used was a fibrosarcoma which had arisen
spontaneously in a (Lewisx DA) F1 hlybrid
rat, but which also grew well after injec-
tion into the footpad of normal (PVG/cx
DA) F1 hybrid rats. In the first experi-
ments 5 x 105 viable fibrosarcoma cells
were inoculated into the footpad of
(PVG/cxDA) F1 hybrid rats 1, 2, 3, 5 or 7
days after 5 x 105 W256 cells had been
injected into the contralateral footpad.
Unless fibrosarcoma cells were adminis-
tered within one day of the W256 cells
challenge in the contralateral footpad, the
second inoculum did not give rise to a
visible tumour. There was no modification
ofthe growth ofthe W256 tumour in these
rats at any time, in comparison with
tumour growth in the footpads of the
control group.
In other experiments, in which a lethal
dose of fibrosarcoma cells (106) was injec-
ted i.v. at various times after inoculation
ofW256 cells into the footpad, the growth
of the latter tumour was unaffected. In
these rats, injection of W256 cells into the
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footpad afforded completeprotection with-
in one day against the i.v. administration
offibrosarcoma cells.
DISCUSSION
The mutual influence exerted on the
growth of each other by two inocula of
tumour cells which had been administered
to the samehost has been examined. It was
found that following the injection ofW256
cells into one footpad, the growth of a
second, similar inoculum in the contra-
lateral footpad was prevented, even if
this was administered within 24 h of the
first. If the second challenge was adminis-
tered by the i.v. route and contained
sufficient W256 cells to be lethal ifgiven to
a normal animal, systemic tumours de-
veloped unless an interval ofatleast 4 days
had elapsed since the initial footpad
challenge. As regards the influence of the
second inoculum on the progress of the
first, significant augmentation of the
growth of the initial tumour was observed
to follow re-challenge with viable tumour
cells provided that these were adminis-
tered within 7 days, if in the footpad, or
within 3 days ifi.v. The injection ofan un-
related tumour failed to influence growth
ofthe initial inoculum ofW256 cells in the
footpad, although non-specific immunity
induced by W256 inoculation prevented
growth ofthe unrelated tumour ifinjection
of this was deferred for more than one
day.
The discrepancy between thefates ofthe
secondary inocula of W256 cells adminis-
tered via different routes may indicate
that after i.v. injection tumour cells were
established more rapidly in the lungs than
in the footpad with cells injected s.c. In
this way, they may have evaded the
developing immune response. However, in
the absence of information on the re-
sponse to a range of i.v. doses of tumour
cells, it is not feasible to clarify this point.
Similarly, no significance can be attributed
to the apparently earlier onset of concur-
rent immunity directed against the fibro-
sarcoma in comparison with the W256
cells administered i.v. without the results
of injection of a range of doses of the two
tumours.
That cross-reactivity should be demon-
strable between two tumours of such
different morphology and origin indicates
that the concomitant immunity observed
was very non-specifically based. In con-
trast, the augmentation ofthe growth of a
pre-existing tumour as a result of a second
exposure of the host to tumour cells was
characterized by a greater degree of
specificity. Apart from the requirement for
identity with the cells of the first inocu-
lum, it was necessary for the tumour cells
in the second inoculation to be viable for
them to modify the growth ofthe primary
tumour. This requirement for viability
may reflect a necessity for tumour cell
proliferation in, or emigration from, the
footpad ifthe host's immune response is to
be influenced.
There are several possiblewayswhereby
the secondary tumour inocula could have
influenced the course of the initial tu-
mour. Augmentation of the growth of a
footpad tumour in a rat bearing pulmon-
ary tumour as a result of i.v. injection of
cells is most likely to have been consequent
upon general debility of the host. The
increased size attained by footpad tu-
mours in rats which had received a further
inoculum of tumour cells in the contra-
lateral paw, may have resulted from
enhancement, ashas beenwelldocumented
in experiments in which tumour cells were
injected before tumour transplantation
(Kaliss et al., 1953). Alternatively, the
selective recruitment of host lymphocytes
with the appropriate reactivity away from
the primary tumour may have interfered
with the host's immune response to it
(Ford and Atkins, 1971; Sprent, Miller and
Mitchell, 1971). The limitation of the
augmentation to tumourre-challengewith-
in a week of the primary inoculum would
favour this interpretation.
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